Microwave versus radiofrequency ablation for the treatment of liver malignancies: a randomized controlled phase 2 trial

Aleksandar Radosevic[1*+], Rita Quesada[2+], Clara Serlavos[1], Juan Sánchez[1], Ander Zugazaga[1], Ana Sierra[1], Susana Coll[3], Marcos Busto[1], Guadalupe Aguilar[1], Daniel Flores[1], Javier Arce[1], José María Maiques[1], Montserrat Garcia-Retortillo[3], José Antonio Carrion[3], Laura Visa[4], María Villamonte[5], Eva Pueyo[5], Enrique Berjano[6], Macarena Trujillo[7], Patricia Sánchez-Velázquez[5], Luís Grande[5], Fernando Burdio[5]

[+]These authors contributed equally to this work as co-first authors.

[1]Department of Radiology, Hospital del Mar, Barcelona, Spain; [2]Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; [3]Hepatology section, Gastroenterology Department, Hospital del Mar. IMIM. Barcelona, Spain.; [4]Department of Oncology-IMIM-Ciberonc, Hospital del Mar, Barcelona, Spain; [5]Department of Surgery, Hospital del Mar, Barcelona, Spain, [6]BioMIT, Department of Electronic Engineering, Universitat Politècnica de València, Valencia, Spain; [7]BioMIT, Department of Applied Mathematics, Universitat Politècnica de València, Valencia, Spain.



Figure S2 (Supplementary): Each ablation zone was semiautomatically segmented and the volume calculated automatically. The line of segmentation followed the border between the unenhanced ablated tissue and the surrounding, enhancing parenchyma. A 1-month portal phase CT scan images were used in all but two patients. For these two patients, the MRI images were used in a similar fashion. Three corresponding diameters were manually determined from multiplanar reconstruction following the applicator track.